The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris | Zendy

Nathan P. Wiederhold | Zendy; Laura K. Najvar | Zendy; Rosie Jaramillo | Zendy; Marcos Olivo | Zendy; Hoja P. Patterson | Zendy; April Connell | Zendy; Yoshiko Fukuda | Zendy; Junichi Mitsuyama | Zendy; Gabriel Catano | Zendy; Thomas F. Patterson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris

Author(s) -

Nathan P. Wiederhold,

Laura K. Najvar,

Rosie Jaramillo,

Marcos Olivo,

Hoja P. Patterson,

April Connell,

Yoshiko Fukuda,

Junichi Mitsuyama,

Gabriel Catano,

Thomas F. Patterson

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02198-19

Subject(s) - in vivo , in vitro , candida auris , microbiology and biotechnology , chemistry , biology , antifungal , biochemistry

The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 log 10 CFU/g) compared to control (0% survival and 7.09 log 10 CFU/g) ( P < 0.01).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research